North China Pharmaceutical: Subsidiary company Huasheng Company received the CEP certificate of chemical raw material drug sulfamonomethoxine B.

North China Pharmaceutical announced that its wholly-owned subsidiary, Huasheng Company, has received the European Pharmacopoeia suitability certificate for the chemical raw material drug Colistin B sulphate issued by the European Drug Quality Management Agency. The acquisition of this certificate indicates the recognition and approval of the quality of this raw material drug by the European market regulations and signifies that the raw material drug product can be sold in the European market. Among the domestic producers of Colistin B sulphate raw materials, there are a total of 3 companies that have obtained a Certificate of Suitability (CEP), and Huasheng Company is the third company to receive this certificate. The total research and development expenditure for this drug is 10.99 million yuan.